SCHEDULE 13G: Capital World Investors Discloses 7.3% Passive Stake in Ionis Pharmaceuticals
Beneficial Ownership Report
Capital World Investors has reported a 7.3% beneficial ownership stake in Ionis Pharmaceuticals, Inc., holding 11,465,413 shares of common stock as of December 31, 2024.
Summary
- Capital World Investors (CWI) reported beneficial ownership of 11,465,413 shares of Ionis Pharmaceuticals, Inc. common stock.
- This ownership represents 7.3% of the 157,897,287 shares of common stock believed to be outstanding.
- CWI, a division of Capital Research and Management Company, holds sole voting power and sole dispositive power over all 11,465,413 shares.
- The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ionis Pharmaceuticals, Inc.
Sentiment
Score: 6
Explanation: The filing itself is a neutral regulatory disclosure. However, the disclosure of a significant passive stake by a major institutional investor like Capital World Investors can be interpreted positively by the market as a vote of confidence in Ionis Pharmaceuticals, Inc.
Positives
- Capital World Investors, a prominent institutional investor, holds a significant 7.3% stake in Ionis Pharmaceuticals, which may be interpreted as a vote of confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
This filing reflects a significant institutional investment in the biotechnology and pharmaceutical sector, a common practice for large asset managers like Capital World Investors seeking long-term positions in established companies within the industry.
Stakeholder Impact
- Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company's long-term prospects and stability.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period for ownership). |
| 02/12/2025 | Date of filing of this Schedule 13G statement. |
Recommendation
holdKeywords
Ionis Pharmaceuticals, Capital World Investors, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.